While oncology steals the limelight, some firms are harnessing the technologies and R&D strategies of precision medicine to develop combination drug/diagnostic products for large-population, non-oncology diseases. They are betting that as scientific knowledge improves and the regulatory process becomes more hospitable, payors and other stakeholders will take a fresh look at a field that has largely taken a backseat.
High-profile successes in cancer, including the recent approval and launch of Genentech Inc./Daiichi Sankyo Co. Ltd.’s Zelboraf (vemurafenib)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?